KalVista Pharmaceuticals (KALV) EBT (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly EBT of -$57.9 million in Q3 2025, down 250.25% quarter-over-quarter from $38.6 million in Q2 2025, and down 43.26% year-over-year from -$102.1 million in Q3 2024.
KalVista Pharmaceuticals' EBT history runs 12 years deep, the most recent figure standing at -$57.9 million for Q3 2025.
- In Q3 2025, EBT fell 43.26% year-over-year to -$57.9 million; the TTM figure through Jul 2025 stood at -$104.3 million (down 50.89% YoY), while the FY2025 annual figure was -$88.4 million, down 67.88% from the prior year.
- EBT came in at -$57.9 million for Q3 2025 at KalVista Pharmaceuticals, down from $38.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of $38.6 million in Q2 2025 to a low of -$57.9 million in Q3 2025.
- A 5-year average of -$22.0 million and a median of -$26.3 million in 2022 frame the typical range for EBT.
- Across the five-year window, EBT sank 111.06% in 2022 and jumped 194.87% in 2024, its largest moves.
- KalVista Pharmaceuticals' EBT stood at -$23.3 million in 2021, then decreased by 9.1% to -$25.4 million in 2022, then retreated by 13.9% to -$29.0 million in 2023, then slumped by 53.45% to -$44.5 million in 2024, then slumped by 30.33% to -$57.9 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$57.9 million, $38.6 million, and -$44.5 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -57.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -57.94 Mn |
| Apr 30, 2025 | 38.56 Mn |
| Oct 31, 2024 | -44.45 Mn |
| Jul 31, 2024 | -40.44 Mn |
| Apr 30, 2024 | 29.33 Mn |
| Jan 31, 2024 | -29.03 Mn |
| Oct 31, 2023 | -28.97 Mn |
| Jul 31, 2023 | -28.17 Mn |
| Apr 30, 2023 | -30.92 Mn |
| Jan 31, 2023 | -26.21 Mn |
| Oct 31, 2022 | -25.43 Mn |
| Jul 31, 2022 | -26.07 Mn |
| Apr 30, 2022 | -26.54 Mn |
| Jan 31, 2022 | -26.43 Mn |
| Oct 31, 2021 | -23.31 Mn |
| Jul 31, 2021 | -19.24 Mn |
| Apr 30, 2021 | -17.73 Mn |
| Jan 31, 2021 | -12.52 Mn |
| Oct 31, 2020 | -12.59 Mn |
| Jul 31, 2020 | -14.18 Mn |
| Apr 30, 2020 | -8.59 Mn |
| Jan 31, 2020 | -12.35 Mn |
| Oct 31, 2019 | -8.78 Mn |
| Jul 31, 2019 | -8.97 Mn |
| Apr 30, 2019 | -10.88 Mn |
| Jan 31, 2019 | -5.94 Mn |
| Oct 31, 2018 | -4.69 Mn |
| Jul 31, 2018 | -6.92 Mn |
| Apr 30, 2018 | -2.90 Mn |
| Jan 31, 2018 | -4.33 Mn |
| Oct 31, 2017 | -5.94 Mn |
| Jul 31, 2017 | -5.45 Mn |
| Apr 30, 2017 | -5.08 Mn |
| Jan 31, 2017 | -8.11 Mn |
| Oct 31, 2016 | -4.02 Mn |
| Jul 31, 2016 | -5.11 Mn |
| Mar 31, 2016 | -6.60 Mn |
| Dec 31, 2015 | -5.66 Mn |
| Sep 30, 2015 | -4.99 Mn |
| Jun 30, 2015 | -5.83 Mn |
| Mar 31, 2015 | -5.18 Mn |
| Sep 30, 2014 | -3.92 Mn |
| Jun 30, 2014 | -2.52 Mn |
| Mar 31, 2014 | -2.02 Mn |